Einleitung wieder einblenden
EUCTR2018-000174-29

Clinical Phase III study in patients undergoing surgery to confirm ability of remimazolam to induce hypnotic effect in comparison with propofol

Datenbasis: WHO (Import vom 27.09.2020)
Geändert: 02.08.2020
Krankheitskategorie:

Health conditions (Datenquelle: WHO)

Induction and maintenance of general anaesthesia (GA)
MedDRA version: 20.0Level: LLTClassification code 10018061Term: General anesthesiaSystem Organ Class: 100000004865
MedDRA version: 20.0Level: LLTClassification code 10054434Term: Induction and maintenance of anesthesiaSystem Organ Class: 100000004865;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]

Interventions (Datenquelle: WHO)


Product Name: Remimazolam
Product Code: CNS7056
Pharmaceutical Form: Lyophilisate for solution for injection
INN or Proposed INN: Remimazolam
Current Sponsor code: CNS7056
Other descriptive name: REMIMAZOLAM
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 2-

Trade Name: Propofol
Product Name: Propofol
Pharmaceutical Form: Emulsion for injection/infusion
INN or Proposed INN: PROPOFOL
Other descriptive name: PROPOFOL
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 20-

Inclusion/Exclusion Criteria (Datenquelle: WHO)

Inclusion criteria:
In order to be eligible to participate in this trial, an individual must meet all of the following criteria:
• Male or female ASA III / IV patients, at least 18 years old, scheduled for an elective surgical procedure of a minimum duration of approximately 90 minutes under GA and planned to be extubated immediately post-operatively
• Total intravenous GA with the requirement for mechanical ventilation via endotracheal tube and necessary invasive BP monitoring either due to severity of illness, severity of concomitant diseases, type of surgery or decisions of the anaesthesia staff.
• Patients scheduled to stay in the hospital long enough after the surgical procedure to perform all trial follow-up procedures (~1 day)
• For female patients of childbearing potential: Negative result of a urine pregnancy test taken shortly before the start of the administration of the IMP as well as consent to use highly effective birth control during the trial period (from the time of consent until the end of the trial follow-up procedures). Women who had their last menstruation at least two years ago or who underwent surgical interventions (surgical birth control, bilateral oophorectomy, hysterectomy, etc.) are regarded as having no childbearing potential.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 350
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 150

Exclusion criteria:
An individual who meets any of the following criteria will be excluded from participation in this trial:
- Patients scheduled for spinal anaesthesia, epidural anaesthesia (central neuroaxial anaesthesia) or regional anaesthesia. The placement of a peridural catheter with a test dose application (up to 3 mL) to verify correct positioning to achieve post-operative analgesia and the regional administration of local anaesthetic for post-operative analgesia after wound closure is accepted.
- Patients undergoing transplant surgery, cardiac surgery, intracranial neurosurgery, emergency surgery, or any surgical procedure with the need for or scheduled for post-operative ventilator support
- Patients undergoing surgical procedures that require keeping the BP at a high level, e.g. surgical procedures in beach chair position
- Patients with severe hypertension, i.e., one baseline result of systolic BP 200 mmHg or more and / or diastolic BP of 120 mmHg or more. Baseline is defined as the time after signature of ICF and before arrival in the OR suite.
- Patients with total bilirubin of =3.0 mg/dL or =3 times increase in aspartate aminotransferase or alanine aminotransferase than the institutional reference range in laboratory tests during screening.
- Patients with end-stage renal disease requiring scheduled dialysis
- Patients with known anaphylactic reactions to benzodiazepines, propofol, opioid analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), dextran, neuromuscular blocking agents, flumazenil, naloxone, or other anaesthetic agents, or a medical condition such that these agents are contraindicated (according to local label)
- Presence of acute alcoholic or illicit drug intoxication, shock or coma state
- Known current dependency on central nervous system depressant drugs or alcohol
- Patients with gastroparesis or delayed gastric emptying, gastric reflux or any other increased risk for gastric aspiration
- Patients with an anticipated (small mouth opening, impaired neck movement, goitre, head and neck tumours or any other anatomical reason) or known difficult airways, known difficulties in airway maintenance or mask ventilation.
- Patients in whom NCT may not provide results due to organic defect of the brain or forehead, or any neurologic disease interfering with the EEG monitoring
- Patients on treatment with valproate
- Any pregnant or breast-feeding patient
Patients who participated in any clinical trial within 30 days prior to the beginning of administration of the IMP.
- Any patient judged to lack the ability to give informed consent or perform the trial assessments (e.g., due to dementia)
- Any patient judged by the principal investigator (PI) or sub-investigator to be inappropriate for the trial for any other reason

Weitere Angaben zur Studie im WHO-Primärregister

https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000174-29

Weitere Angaben zur Studie aus der Datenbank der WHO (ICTRP)

http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2018-000174-29-FR

Weitere Informationen zur Studie

Registrationsdatum der Studie

26.07.2018

Einschluss der ersten teilnehmenden Person

21.09.2018

Rekrutierungsstatus

Not Recruiting

Wissenschaftlicher Titel (Datenquelle: WHO)

Phase III confirmatory efficacy and safety trial of remimazolam (CNS7056) compared with propofol for intravenous anaesthesia during elective surgery

Studientyp (Datenquelle: WHO)

Interventional clinical trial of medicinal product

Design der Studie (Datenquelle: WHO)

Controlled: yes
Randomised: yes
Open: no
Single blind: yes
Double blind: no
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: yes
Placebo: no
Other: no
Number of treatment arms in the trial: 2

Phase (Datenquelle: WHO)

Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no

Primäre Endpunkte (Datenquelle: WHO)

Timepoint(s) of evaluation of this end point: During the maintenance phase of the GA;Primary end point(s): The primary efficacy endpoint (PEP) is the anaesthetic effect of remimazolam and propofol assessed as percent (%) of time of Narcotrend (NCT) Index =60 during the maintenance phase of the GA defined as the time between the first skin incision and the completion of the last skin suture;Secondary Objective: This is a confirmatory trial to establish superior haemodynamic stability associated with the use of remimazolam compared with propofol for the induction and maintenance of GA for the purpose of elective surgery.;Main Objective: This is a confirmatory trial to establish non-inferior efficacy of remimazolam compared with propofol for induction and maintenance of GA for the purpose of elective surgery.

Sekundäre Endpunkte (Datenquelle: WHO)

Secondary end point(s): The key secondary endpoint (KSE) is haemodynamic instability defined as critical decrease(s) in mean arterial blood pressure (MAP) between start of IMP and 15 minutes after the first skin incision.
For this endpoint, each event from the following categories will be counted and summed up per patient:
• Incidence of MAP dropping below 65 mmHg for at least 1 minute duration
• Incidence of a MAP decrease of more than 20% below the calculated (mean) baseline MAP value for at least 1 minute duration
• Incidence of a MAP decrease of more than 30% below the calculated (mean) baseline MAP value for at least 1 minute duration
• Number of norepinephrine boluses (0.01 mg) required or, if an infusion is used to maintain MAP equal to or above 65 mmHg, then each time interval of 2 minutes duration of continuous norepinephrine infusion will be counted as one event.
The baseline MAP is calculated based on all blood pressure (BP) measurements that are taken after signing the informed consent form (ICF) and before arrival at the operation room (OR) suite.
This endpoint is a safety endpoint.
Other secondary endpoints for efficacy comprise
• Percentage of time of NCT index (NCI) =60 and =40 during the maintenance phase
• Percentage of time of NCI <40 during the maintenance phase
• Percentage of patients with NCI =60 and =40 during =90% of the maintenance phase
• Percentage of patients who were administered rescue sedative medication
• The occurrence of intra-operative awakening (explicit awareness)
• Time from start of IMP to first NCI =60
• Time from start of IMP to loss of palpebral reflex
• Time from start of IMP to loss of consciousness (LOC, i.e., modified observer’s assessment of alertness / sedation [MOAA/S] = 0)
• Time from stop of IMP to response to verbal command (MOAA/S =4)
• Time from stop of IMP to end of extubation
• Time from stop of IMP to orientation to time, place, person and situation
• Time from stop of IMP to Modified Aldrete Score = 10
• Investigator’s overall satisfaction with IMP;Timepoint(s) of evaluation of this end point: During the maintenance phase of the GA

Kontakt für Auskünfte (Datenquelle: WHO)

PAION UK Limited

Ergebnisse der Studie (Datenquelle: WHO)

Zusammenfassung der Ergebnisse

Phase III confirmatory efficacy and safety trial of remimazolam (CNS7056) compared with propofol for intravenous anaesthesia during elective surgery

Link zu den Ergebnissen im Primärregister

noch keine Angaben verfügbar

Angaben zur Verfügbarkeit von individuellen Teilnehmerdaten

noch keine Angaben verfügbar

Studiendurchführungsorte

Durchführungsländer (Datenquelle: WHO)

Belgium, Denmark, France, Germany, Italy, Netherlands, Switzerland, United Kingdom

Kontakt für weitere Auskünfte zur Studie

Kontakt für allgemeine Auskünfte (Datenquelle: WHO)

Clinical Trial Information
Martinstrasse 10-12
PAION Deutschland GmbH
00492414453101
info@paion.com

Kontakt für wissenschaftliche Auskünfte (Datenquelle: WHO)

Clinical Trial Information
Martinstrasse 10-12
PAION Deutschland GmbH
00492414453101
info@paion.com

Studienverantwortliche

Hauptsponsor (Datenquelle: WHO)

PAION UK Limited

Weitere Studienidentifikationsnummern

Secondary ID (Datenquelle: WHO)

CNS7056-022
2018-000174-29-DE